170 related articles for article (PubMed ID: 19457483)
21. Advances in drug treatment of dyslipidemia: focus on atorvastatin.
Davignon J
Can J Cardiol; 1998 May; 14 Suppl B():28B-38B. PubMed ID: 9627539
[TBL] [Abstract][Full Text] [Related]
22. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
[TBL] [Abstract][Full Text] [Related]
23. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
Vishwanath R; Hemphill LC
J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
[TBL] [Abstract][Full Text] [Related]
24. Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism.
Hirano K; Ikegami C; Tsujii K; Zhang Z; Matsuura F; Nakagawa-Toyama Y; Koseki M; Masuda D; Maruyama T; Shimomura I; Ueda Y; Yamashita S
Arterioscler Thromb Vasc Biol; 2005 Nov; 25(11):2422-7. PubMed ID: 16151015
[TBL] [Abstract][Full Text] [Related]
25. HDL-C: role as a risk modifier.
Barter P
Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
[TBL] [Abstract][Full Text] [Related]
26. Effect of probucol on elderly hypercholesterolemic patients in the FAST study.
Sawayama Y; Maeda S; Ohnishi H; Okada K; Hayashi J
Fukuoka Igaku Zasshi; 2006 Jan; 97(1):15-24. PubMed ID: 16613215
[TBL] [Abstract][Full Text] [Related]
27. Is there a problem with ezetimibe or just ENHANCEd hype?
Whayne TF
Angiology; 2008 Dec-2009 Jan; 59(6):661-3. PubMed ID: 18796445
[No Abstract] [Full Text] [Related]
28. Clinical applications of long-term LDL-apheresis on and beyond refractory hypercholesterolemia.
Mabuchi H; Higashikata T; Kawashiri MA
Transfus Apher Sci; 2004 Jun; 30(3):233-43. PubMed ID: 15172629
[TBL] [Abstract][Full Text] [Related]
29. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades.
Elis A; Zhou R; Stein EA
Am J Cardiol; 2011 Jul; 108(2):223-6. PubMed ID: 21545982
[TBL] [Abstract][Full Text] [Related]
30. Rationale and Design of the PROSPECTIVE Trial: Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease.
Yamashita S; Masuda D; Ohama T; Arai H; Bujo H; Kagimura T; Kita T; Matsuzaki M; Saito Y; Fukushima M; Matsuzawa Y;
J Atheroscler Thromb; 2016 Jun; 23(6):746-56. PubMed ID: 26803913
[TBL] [Abstract][Full Text] [Related]
31. Effect of probucol on serum lipoprotein and apoprotein profiles in renal transplant patients.
Okubo M; Horii A; Kamata K; Takeuchi Y; Tsukamoto Y; Kobayashi N; Sato K; Kumano K; Endo T
Am J Kidney Dis; 1998 Feb; 31(2):356-9. PubMed ID: 9469511
[TBL] [Abstract][Full Text] [Related]
32. Pharmacologic prevention of both restenosis and atherosclerosis progression: AGI-1067, probucol, statins, folic acid and other therapies.
Tardif JC; Grégoire J; Lavoie MA; L'Allier PL
Curr Opin Lipidol; 2003 Dec; 14(6):615-20. PubMed ID: 14624139
[TBL] [Abstract][Full Text] [Related]
33. Probucol therapy improves long-term (>10-year) survival after complete revascularization: a propensity analysis.
Kasai T; Miyauchi K; Kubota N; Kajimoto K; Amano A; Daida H
Atherosclerosis; 2012 Feb; 220(2):463-9. PubMed ID: 22024277
[TBL] [Abstract][Full Text] [Related]
34. Development and Clinical Application of an Enzyme-Linked Immunosorbent Assay for Oxidized High-Density Lipoprotein.
Okada T; Sumida M; Ohama T; Katayama Y; Saga A; Inui H; Kanno K; Masuda D; Koseki M; Nishida M; Sakata Y; Yamashita S
J Atheroscler Thromb; 2021 Jul; 28(7):703-715. PubMed ID: 33028763
[TBL] [Abstract][Full Text] [Related]
35. New Horizons for Probucol, an Old, Mysterious Drug.
Yamashita S; Masuda D; Matsuzawa Y
J Atheroscler Thromb; 2021 Feb; 28(2):100-102. PubMed ID: 32507832
[No Abstract] [Full Text] [Related]
36. Biliary lipid composition in heterozygous familial hypercholesterolemia and influence of treatment with probucol.
Tanno N; Oikawa S; Koizumi M; Kotake H; Hirakawa H; Kanazawa Y; Toyota T
Dig Dis Sci; 1994 Jul; 39(7):1586-91. PubMed ID: 8026274
[TBL] [Abstract][Full Text] [Related]
37. Non-macrophage-related accumulation of cholesterol during probucol treatment in familial hypercholesterolemia: report of two cases.
Nakamura T; Ueyama Y; Funahashi T; Yamashita S; Takemura KK; Kubo M; Yamada K; Matsuzawa Y
Atherosclerosis; 1992 Feb; 92(2-3):193-202. PubMed ID: 1632848
[TBL] [Abstract][Full Text] [Related]
38. Probucol.
Pfuetze KD; Dujovne CA
Curr Atheroscler Rep; 2000 Jan; 2(1):47-57. PubMed ID: 11122724
[TBL] [Abstract][Full Text] [Related]
39. New Evidence of Probucol on Cardiovascular Events.
Hirata KI
J Atheroscler Thromb; 2021 Feb; 28(2):97-99. PubMed ID: 33229816
[No Abstract] [Full Text] [Related]
40. Safety and efficacy of probucol during one year of administration.
Nash DT
J Clin Pharmacol; 1974; 14(8):470-5. PubMed ID: 4605082
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
